GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
== Network == Today, the IIR has 59 member countries representing over two-thirds of the global population. According to their annual financial contributions to the IIR, these member countries are divided into six categories, and this determines the services they receive and their level of voting power within the IIR. Member countries take part in IIR activities via their delegates and their nominated commission members. The delegates and commission members determine IIR priorities and take part in the IIR scientific activities and working groups, and develop recommendations. Member countries are entitled to host several IIR conferences and meetings per year.
== External links == NASA Spinoff homepage NASA Spinoff back issues archive NASA spinoff database Home and City – relating everyday life to NASA research NASA Benefits to You NASA Office of the Chief Technologist NASA STI Program "The Economic Impacts of the U.S. Space Program" by Jerome Schnee, Rutgers University "A Sustainable Method for Quantifying the Benefits of NASA Technology Transfer"
Between 1634 and 1637, the enthusiasm for the new flowers in the Netherlands triggered a speculative frenzy now known as the tulip mania, the first recorded speculative bubble in history, that eventually led to the collapse of the market three years later. Tulip bulbs had become so expensive that they were treated as a form of currency, or rather, as futures, forcing the Dutch government to introduce trading restrictions on the bulbs. The 'Semper Augustus' was the most expensive tulip during the 17th-century tulip mania. At the height of 'Tulip mania' this tulip was even sold for 10.000 guilders (equivalent to approx. €130.000 in 2024). After seeing the tulip in the garden of Dr. Adriaan Pauw, a director of the Dutch East India Company, Nicolas van Wassenaer wrote in 1624 that "The colour is white, with carmine on a blue base, and with an unbroken flame right to the top". The 'Semper Augustus' was actually not a tulip variety, but rather a tulip affected by the tulip mosaic virus. With limited specimens in existence at the time and most owned by Pauw, his refusal to sell any flowers, despite wildly escalating offers, is believed by some to have sparked the mania. Around this time, the ceramic tulipiere was devised for the display of cut flowers stem by stem. Vases and bouquets, usually including tulips, often appeared in Dutch still-life painting. To this day, tulips are associated with the Netherlands, and the cultivated forms of the tulip are often called "Dutch tulips". The Netherlands has the world's largest permanent display of tulips at the Keukenhof.
The neurotransmitter serotonin, a non-selective serotonin receptor agonist, strongly increases oxytocin levels, by up to 12-fold, when given via intracerebroventricular injection in rodents. This can be blocked by various serotonin receptor antagonists. Selective serotonin 5-HT1A receptor agonists like 8-OH-DPAT, buspirone, and ipsapirone increase oxytocin levels in rodents. Both 8-OH-DPAT and buspirone maximally increased oxytocin levels by around 9-fold, whereas ipsapirone increased oxytocin levels by only around 3-fold. Similarly to serotonin 5-HT1A receptor agonists, the serotonin 5-HT2 receptor agonist DOI increases oxytocin levels in rodents, with a maximal increase of around 5- to 10-fold depending on the dose. The serotonin 5-HT2A receptor antagonist ketanserin reduced the increase in oxytocin levels induced by DOI by about 90%, while addition of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist LY-53857 fully blocked the increase. The non-selective but preferential serotonin 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) maximally increased oxytocin levels by around 6-fold, with the increases minimally affected by ketanserin but abolished by non-selective serotonin 5-HT2 receptor antagonists including LY-53857, mianserin, and metergoline. Another non-selective but preferential serotonin 5-HT2C receptor agonist, MK-212, robustly increases oxytocin levels in rodents as well. The serotonin 5-HT3 receptor agonists SR-57277 and m-CPBG and the serotonin 5-HT4 receptor agonist RS-67506 increase oxytocin levels maximally by several-fold in rodents.
PLGA, PLG, or poly(lactic-co-glycolic) acid (CAS: 26780-50-7 ) is a biodegradable, biocompatible copolymer of lactic and glycolic acid used widely in biomedical devices and tissue-engineering materials approved by the Food and Drug Administration (FDA). PLGA is synthesized by means of ring-opening co-polymerization of two different monomers: glycolide and lactide, the cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid, respectively. The polymer has emerged as platform for advanced drug delivery systems, including nanoparticles, because of its tunable degradation behavior and ability to encapsulate different therapeutic agents. Recent research features its growing role in precision medicine and targeted therapies, specifically in cancer treatment and controlled release applications.
Sources: en.wikipedia.org
Additional evidence supporting the concept of an RNA world has resulted from research on viroids, the first representatives of a novel domain of "subviral pathogens". Viroids infect plants, where most are pathogens, and consist of short stretches of highly complementary, circular, single-stranded and non-coding RNA without a protein coat. They are extremely small, ranging from 246 to 467 nucleobases, compared to the smallest known viruses capable of causing an infection, with genomes about 2,000 nucleobases in length. Based on their characteristic properties, in 1989 plant biologist Theodor Diener argued that viroids are more plausible living relics of the RNA world than introns and other RNAs considered candidates at the time. Diener's hypothesis would be expanded by the research group of Ricardo Flores, and gained a broader audience when in 2014, a New York Times science writer published a popularized version of the proposal. The characteristics of viroids highlighted as consistent with an RNA world were their small size, high guanine and cytosine content, circular structure, structural periodicity, the lack of protein-coding ability and, in some cases, ribozyme-mediated replication. One aspect critics of the hypothesis have focused on is that the exclusive hosts of all known viroids, angiosperms, did not evolve until billions of years after the RNA world was replaced, making viroids more likely to have arisen through later evolutionary mechanisms unrelated to the RNA world than to have survived via a cryptic host over that extended period.
The endogenous α-amino acids L-leucine and L-isoleucine, which closely resemble pregabalin and the other gabapentinoids in chemical structure, are apparent ligands of the α2δ VGCC subunit with similar affinity as the gabapentinoids (e.g., IC50=71 nM for L-isoleucine), and are present in human cerebrospinal fluid at micromolar concentrations (e.g., 12.9 μM for L-leucine, 4.8 μM for L-isoleucine). It has been theorized that they may be the endogenous ligands of the subunit and that they may competitively antagonize the effects of gabapentinoids. In accordance, while gabapentinoids like pregabalin and gabapentin have nanomolar affinities for the α2δ subunit, their potencies in vivo are in the low micromolar range, and competition for binding by endogenous L-amino acids has been said to likely be responsible for this discrepancy. Pregabalin was found to possess 6-fold higher affinity than gabapentin for α2δ subunit-containing VGCCs in one study. However, another study found that pregabalin and gabapentin had similar affinities for the human recombinant α2δ-1 subunit (Ki=32 nM and 40 nM, respectively). In any case, pregabalin is 2 to 4 times more potent than gabapentin as an analgesic and, in animals, appears to be 3 to 10 times more potent than gabapentin as an anticonvulsant.
== Early years == This hypothesis was first proposed by Jaak Panksepp in a 1979 paper, in which he speculated that autism might be "an emotional disturbance arising from an upset in the opiate systems in the brain". Kalle Reichelt then emerged as one of the leading advocates of this theory, publishing papers alleging that "the patterns of peptides and associated proteins from urinary samples [from people with autism] differ considerably from each other and from normal controls." In addition, Reichelt's research has concluded that autistic individuals have increased levels of these peptides in their cerebrospinal fluid. Additionally, in a 1991 paper, Reichelt argued that gluten and casein may play a causative role in autism, as the incomplete digestion thereof may produce certain opioid peptides. Thus, those, such as Paul Shattock, who advocate this theory also advocate the use of a gluten-free, casein-free diet as a treatment for autism.
=== Organization === The E.S.PKU has 41 member organizations from across Europe. One of the later countries to join was the French association Les Feux Follets in 2013. A member organization has to be a non-profit organization on a national level dealing with phenylketonuria patients. The E.S.PKU executive board is elected by the annual general meeting every three years and consists of volunteers. The Scientific advisory committee oversees projects like the European Guidelines and collects data to support studies in the field of phenylketonuria. Besides the political work (such as METAB-ERN or EXCEMED) on European level, the E.S.PKU hosts an annual conference.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.